Developer docs
API playgroundTry for free, no card

Search company profiles

Suanfarma Biotech

Full company profile

uuid0008ccj

Namestring
Suanfarma Biotech
Legal namestring
SUANFARMA
Websiteurl
suanfarma.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Suanfarma Biotech, founded in 1993 and headquartered in Alcobendas (Madrid), Spain, is a privately held manufacturer of active pharmaceutical ingredients (APIs) and contract development and manufacturing (CDMO) services. It operates as a portfolio company of the private equity firm ARCHIMED. Suanfarma produces both human APIs (spanning antibiotics, cardiovascular, and oncology molecules such as Ribociclib Succinate and Bisoprolol) and veterinary APIs (including Albendazole, Tiamulin, and Fluralaner), alongside chemical intermediates, and serves pharmaceutical and animal-health customers globally. Following the December 2025 divestiture of its nutraceutical ingredients subsidiary SuanNutra, the company is focused on its API and CDMO core.

The company runs an integrated fermentation and chemical synthesis platform across two GMP-certified European manufacturing sites: Cipan in Castanheira do Ribatejo, Portugal (described as one of the largest fully GMP-compliant fermentation facilities in Europe) and Rovereto in Italy (acquired from Sandoz/Novartis in 2019). Technical capabilities include industrial-scale fermentation using bacteria, yeast, and fungi, flow chemistry for safer and more sustainable reactions, digital twin process simulation (claimed to cut tech transfer timelines by 20-30%), IoT-and-AI predictive maintenance, and OEB 4 high-potency containment for oncology APIs. The R&D function develops 2-3 new products per year.

Suanfarma generates revenue through three streams: direct API sales (proprietary and generic APIs to pharma companies), CDMO services (process development, tech transfer, scale-up, and GMP manufacturing), and co-development plus regulatory consulting (dossier preparation and registration support). Distribution is handled through a global network of 10 area offices serving 400+ active customers in more than 70 countries, complemented by selective partner distribution such as UQUIFA for Albendazole. Pricing is quote-based and tailored to volume and regulatory market, with regulatory filings (DMF, CEP, CTD) bundled into the offering across 70+ jurisdictions.

Short descriptiontext

Suanfarma Biotech is a Spain-headquartered, ARCHIMED-backed manufacturer of active pharmaceutical ingredients (APIs) and CDMO services, combining fermentation and chemical synthesis across GMP sites in Portugal and Italy to serve 400+ pharmaceutical and animal-health customers in 75+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersMadrid, Spain
HQ citystring
Madrid
HQ countrystring
Spain
HQ regionstring
Europe
Markets served

Serves global market

Offices10 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
active pharmaceutical ingredients, contract development manufacturing, fermentation API production, veterinary pharmaceutical ingredients, GMP-compliant manufacturing
Industry4 codes
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAGAL
GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
NAICS code2 codes
  • Medicinal and Botanical Manufacturing325411
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Medicinal Chemicals & Botanical Products2833
  • Services-Commercial Physical & Biological Research8731
Product category
Active Pharmaceutical Ingredient (API) Manufacturing and CDMO Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Active Pharmaceutical Ingredients (API) Sales
TypeOne Time License
Description

Manufacturing and sale of high-quality active pharmaceutical ingredients including human APIs, veterinary APIs, and intermediate products. Revenue is generated through direct supply of proprietary and generic APIs to pharmaceutical companies globally.

suanfarma.com
2CDMO (Contract Development and Manufacturing Organization) Services
TypeProfessional Services
Description

End-to-end contract manufacturing and development services including process development, technology transfer, scale-up, and GMP manufacturing for pharmaceutical and biotech companies. Services span from early-stage feasibility through commercial-scale production.

suanfarma.com
3Co-Development and Regulatory Consulting
TypeProfessional Services
Description

Collaborative product development, regulatory strategy, and dossier preparation services for pharmaceutical and biotech partners. Revenue generated through project-based consulting engagements and co-development partnerships.

suanfarma.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Infrastructure, Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1Suanfarma CDMO
Description

Unified brand for Suanfarma's Contract Development and Manufacturing Organization services, encompassing fermentation and chemical synthesis capabilities at Cipan and Rovereto facilities.

suanfarma.com
+1 more record
Core offering1 text field

Suanfarma Biotech develops, manufactures, and globally distributes Active Pharmaceutical Ingredients (human APIs, veterinary APIs, and intermediate products) and provides integrated Contract Development and Manufacturing Organization (CDMO) services combining fermentation and chemical synthesis. Manufacturing is performed at two European GMP-compliant facilities (Cipan in Portugal, Rovereto in Italy) and supplied to pharmaceutical and biotech customers in 75+ countries via direct enterprise sales backed by 10 commercial offices.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 20-30% reduction in technology transfer timelines through Digital Twin technology
+2 more records
Product overview1 text field

Suanfarma is a pharmaceutical company specializing in Active Pharmaceutical Ingredients (APIs) with a diversified portfolio spanning Human APIs (antibiotics, cardiovascular, oncology), Veterinary APIs (antiparasitics, antibiotics), and Intermediate Products. The company operates through two integrated divisions: API Distribution (marketing and distributing proprietary and third-party APIs globally) and CDMO Services (contract manufacturing combining fermentation and chemical synthesis). Manufacturing is conducted at two European GMP-compliant facilities: Cipan in Portugal and Rovereto in Italy. The CDMO platform offers integrated services including process development, technology transfer, scale-up, and commercial manufacturing, with advanced capabilities in flow chemistry and digital twin technology for process optimization.

Product and service9 records
1Human APIs
CategoryActive pharmaceutical ingredients
Description

Active pharmaceutical ingredients for human medicine applications, including antibiotics, cardiovascular treatments (e.g., Bisoprolol), and oncology drugs. Supplied to pharmaceutical and biotech companies globally with full regulatory documentation (DMF, CTD, CEP).

2Veterinary APIs
CategoryVeterinary active pharmaceutical ingredients
Description

Active pharmaceutical ingredients for animal health applications, including antiparasitics (Albendazole, Oxibendazole, Tiamulin, Fluralaner) and antibiotics for livestock and companion animals. Suanfarma was the first European manufacturer to fully supply Tiamulin with CEP and DMF approval for Europe and the USA.

3Intermediate Products
CategoryPharmaceutical intermediates
Description

Pharmaceutical intermediate compounds used as building blocks in the synthesis of active pharmaceutical ingredients, supplied globally to API manufacturers.

4Ribociclib Succinate API
CategoryOncology active pharmaceutical ingredient
Description

Selective CDK4/6 inhibitor API used in targeted anticancer therapy for HR-positive, HER2-negative advanced and metastatic breast cancer. Offered in Polymorphic Form A with purity greater than 98%, produced in OEB 4 GMP-compliant facilities with full DMF and CTD regulatory documentation.

5Suanfarma CDMO Services
CategoryContract development and manufacturing services
Description

Contract Development and Manufacturing Organization services offering integrated end-to-end solutions for API development and manufacturing, combining fermentation and chemical synthesis capabilities. Spans process development, technology transfer, scale-up, and commercial GMP manufacturing for pharmaceutical and biotech partners.

6Fermentation Services
CategoryCDMO bioprocessing services
Description

Industrial-scale bioconversion through fermentation processes that produce complex molecular intermediates from renewable raw materials using bacteria, yeast, or fungi. Includes lab-to-industrial-scale production of APIs and intermediates among the largest fully GMP-compliant fermentation operations in Europe.

7Chemical Synthesis Services
CategoryCDMO chemical synthesis services
Description

Precision chemical synthesis capabilities for API production, including complex reactions, hydrogenations, distillations, crystallizations, and drying processes, integrated with fermentation in modular hybrid production lines for efficient campaign transitions.

8Regulatory and Technical Support Services
CategoryRegulatory affairs and technical documentation services
Description

Comprehensive technical and regulatory package including DMF and CTD documentation, polymorphic form confirmation, impurity characterization, CEP support, and compliance assistance for global market registration across 70+ regulatory markets.

9Co-Development Services
CategoryCo-development and consulting services
Description

Collaborative product development, regulatory strategy, and dossier preparation services for pharmaceutical and biotech partners, leveraging Suanfarma's fermentation and chemical synthesis platform and global regulatory expertise.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1Fundación Lucha contra las Infecciones
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-27
Description

Strategic collaboration between Suanfarma and the Fight Infections Foundation (Fundación Lucha contra las Infecciones), a non-profit entity with over 30 years of scientific leadership in infectious disease research, prevention, and treatment. The partnership supports advanced research in critical areas for global health including HIV, COVID-19, and neglected diseases, aligning with Suanfarma's API development and supply activities.

suanfarma.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-11-08
Description

Suanfarma joined the Child Vaccination Alliance, an initiative established by la Caixa Foundation in collaboration with Gavi, the Vaccine Alliance, and with scientific support from ISGlobal. The alliance provides Spanish companies with an opportunity to contribute to a cooperative project combating child mortality in developing countries. Funds are directed toward vaccine distribution in Mozambique and Ethiopia, targeting pneumonia prevention.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-11-08
Description

Suanfarma participates in the Child Vaccination Alliance alongside Gavi, contributing to vaccination programs for children under 5 in 73 of the world's poorest countries. la Caixa Foundation and the Bill and Melinda Gates Foundation match donations up to 2 million euros.

4Fundación Arraigo
Strategic tierMinorTypeOthers
Description

Suanfarma founded and serves as patron of Fundación Arraigo, established to help migrants in Spain by providing basic education and resources to facilitate labor integration. The foundation has supported 1,950 people, 560 families, and delivered 750 diplomas across multiple training and employment projects.

suanfarma.com
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Suanfarma distributes Albendazole manufactured by UQUIFA at its plant in Mexico. This partnership enables Suanfarma to offer antiparasitic APIs under high quality and accessibility standards, combining UQUIFA's manufacturing capabilities with Suanfarma's global distribution network.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Fareva
TypeBroad incumbent
Description

French privately-held pharmaceutical manufacturer covering APIs, finished dosage forms and cosmetics/industrial manufacturing across Europe. Broad European incumbent with overlapping CDMO/API capabilities.

TypeBroad incumbent
Description

US-headquartered CDMO owned by Permira, focused on small-molecule API development and manufacturing. Established global CDMO incumbent overlapping with Suanfarma's small-molecule API offerings.

3Recipharm
TypeBroad incumbent
Description

Large Swedish CDMO (PE-owned by EQT) covering APIs, finished dosage forms and biologics across many sites. Broader CDMO incumbent that competes with Suanfarma for complex API outsourcing contracts.

TypeDirect peer
Description

Swiss-listed CDMO offering integrated API manufacturing including controlled substances and fermentation-derived molecules, with dual-site European production. Closely comparable in scope, regulatory depth and CDMO platform strategy.

TypeDirect peer
Description

Swiss-headquartered CDMO specializing in API development, including fermentation-derived and highly potent compounds, with Indian manufacturing via the Dishman site. Comparable in fermentation + high-potency API niche.

TypeDirect peer
Description

CDMO arm of AGC offering small-molecule API development and manufacturing including fermentation and chemical synthesis capabilities. Competes directly with Suanfarma CDMO for similar innovator and generic API projects.

TypeBroad incumbent
Description

Chinese CDMO covering small-molecule API and integrated CMC services globally. Representative of the Asian low-cost CDMO competitors against which Suanfarma's European dual-sourcing positioning is increasingly sold.

TypeDirect peer
Description

European API manufacturer spun out of Sanofi in 2022, focused on small-molecule APIs across multiple therapeutic areas with global customer reach. Directly comparable in product portfolio and European industrial API footprint.

TypeDirect peer
Description

Portugal-headquartered CDMO combining chemistry, fermentation and particle engineering for small-molecule APIs. Closest geographic and capability analogue to Suanfarma's Cipan/Portuguese footprint and dual fermentation-chemical synthesis model.

10Olon Group
TypeDirect peer
Description

Italian CDMO and one of the largest global manufacturers of generic APIs with fermentation and chemical synthesis capabilities across multiple sites. Direct European-headquartered peer with overlapping capabilities to Cipan and Rovereto.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment4 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Suanfarma Biotech

Active Pharmaceutical Ingredient (API) Manufacturing and CDMO Servicessuanfarma.com

Suanfarma Biotech is a Spain-headquartered, ARCHIMED-backed manufacturer of active pharmaceutical ingredients (APIs) and CDMO services, combining fermentation and chemical synthesis across GMP sites in Portugal and Italy to serve 400+ pharmaceutical and animal-health customers in 75+ countries.

What Suanfarma Biotech does

Suanfarma Biotech, founded in 1993 and headquartered in Alcobendas (Madrid), Spain, is a privately held manufacturer of active pharmaceutical ingredients (APIs) and contract development and manufacturing (CDMO) services. It operates as a portfolio company of the private equity firm ARCHIMED. Suanfarma produces both human APIs (spanning antibiotics, cardiovascular, and oncology molecules such as Ribociclib Succinate and Bisoprolol) and veterinary APIs (including Albendazole, Tiamulin, and Fluralaner), alongside chemical intermediates, and serves pharmaceutical and animal-health customers globally. Following the December 2025 divestiture of its nutraceutical ingredients subsidiary SuanNutra, the company is focused on its API and CDMO core.

The company runs an integrated fermentation and chemical synthesis platform across two GMP-certified European manufacturing sites: Cipan in Castanheira do Ribatejo, Portugal (described as one of the largest fully GMP-compliant fermentation facilities in Europe) and Rovereto in Italy (acquired from Sandoz/Novartis in 2019). Technical capabilities include industrial-scale fermentation using bacteria, yeast, and fungi, flow chemistry for safer and more sustainable reactions, digital twin process simulation (claimed to cut tech transfer timelines by 20-30%), IoT-and-AI predictive maintenance, and OEB 4 high-potency containment for oncology APIs. The R&D function develops 2-3 new products per year.

Suanfarma generates revenue through three streams: direct API sales (proprietary and generic APIs to pharma companies), CDMO services (process development, tech transfer, scale-up, and GMP manufacturing), and co-development plus regulatory consulting (dossier preparation and registration support). Distribution is handled through a global network of 10 area offices serving 400+ active customers in more than 70 countries, complemented by selective partner distribution such as UQUIFA for Albendazole. Pricing is quote-based and tailored to volume and regulatory market, with regulatory filings (DMF, CEP, CTD) bundled into the offering across 70+ jurisdictions.

Suanfarma Biotech firmographics

Firmographics
Name
Suanfarma Biotech
Legal name
SUANFARMA
Website
https://suanfarma.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
101–250 employees
Short description
Suanfarma Biotech is a Spain-headquartered, ARCHIMED-backed manufacturer of active pharmaceutical ingredients (APIs) and CDMO services, combining fermentation and chemical synthesis across GMP sites in Portugal and Italy to serve 400+ pharmaceutical and animal-health customers in 75+ countries.
Ownership category
akta.pro rank

Suanfarma Biotech industry classification

Industry
Product category
Active Pharmaceutical Ingredient (API) Manufacturing and CDMO Services
NAICS
Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Medicinal Chemicals & Botanical Products (2833), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAGAL
GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)

Keywords

  • Active pharmaceutical ingredients
  • Contract development manufacturing
  • Fermentation API production
  • Veterinary pharmaceutical ingredients
  • GMP-compliant manufacturing

Where Suanfarma Biotech is headquartered

Location

Headquarters

HQ city
Madrid
HQ country
Spain
HQ region
Europe

Offices10 records

Markets served

Suanfarma Biotech business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Infrastructure, Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Active Pharmaceutical Ingredients (API) Sales: Manufacturing and sale of high-quality active pharmaceutical ingredients including human APIs, veterinary APIs, and intermediate products. Revenue is generated through direct supply of proprietary and generic APIs to pharmaceutical companies globally.
  2. CDMO (Contract Development and Manufacturing Organization) Services: End-to-end contract manufacturing and development services including process development, technology transfer, scale-up, and GMP manufacturing for pharmaceutical and biotech companies. Services span from early-stage feasibility through commercial-scale production.
  3. Co-Development and Regulatory Consulting: Collaborative product development, regulatory strategy, and dossier preparation services for pharmaceutical and biotech partners. Revenue generated through project-based consulting engagements and co-development partnerships.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Suanfarma Biotech product offering

Product offering

Core offering

Suanfarma Biotech develops, manufactures, and globally distributes Active Pharmaceutical Ingredients (human APIs, veterinary APIs, and intermediate products) and provides integrated Contract Development and Manufacturing Organization (CDMO) services combining fermentation and chemical synthesis. Manufacturing is performed at two European GMP-compliant facilities (Cipan in Portugal, Rovereto in Italy) and supplied to pharmaceutical and biotech customers in 75+ countries via direct enterprise sales backed by 10 commercial offices.

Product overview

Suanfarma is a pharmaceutical company specializing in Active Pharmaceutical Ingredients (APIs) with a diversified portfolio spanning Human APIs (antibiotics, cardiovascular, oncology), Veterinary APIs (antiparasitics, antibiotics), and Intermediate Products. The company operates through two integrated divisions: API Distribution (marketing and distributing proprietary and third-party APIs globally) and CDMO Services (contract manufacturing combining fermentation and chemical synthesis). Manufacturing is conducted at two European GMP-compliant facilities: Cipan in Portugal and Rovereto in Italy. The CDMO platform offers integrated services including process development, technology transfer, scale-up, and commercial manufacturing, with advanced capabilities in flow chemistry and digital twin technology for process optimization.

Differentiator

Problem solved

Functional benefit

Brands

  • Suanfarma CDMO: Unified brand for Suanfarma's Contract Development and Manufacturing Organization services, encompassing fermentation and chemical synthesis capabilities at Cipan and Rovereto facilities.
  • Suanfarma CDMO

Products and services

  • Human APIs Active pharmaceutical ingredients for human medicine applications, including antibiotics, cardiovascular treatments (e.g., Bisoprolol), and oncology drugs. Supplied to pharmaceutical and biotech companies globally with full regulatory documentation (DMF, CTD, CEP).
  • Veterinary APIs Active pharmaceutical ingredients for animal health applications, including antiparasitics (Albendazole, Oxibendazole, Tiamulin, Fluralaner) and antibiotics for livestock and companion animals. Suanfarma was the first European manufacturer to fully supply Tiamulin with CEP and DMF approval for Europe and the USA.
  • Intermediate Products Pharmaceutical intermediate compounds used as building blocks in the synthesis of active pharmaceutical ingredients, supplied globally to API manufacturers.
  • Ribociclib Succinate API Selective CDK4/6 inhibitor API used in targeted anticancer therapy for HR-positive, HER2-negative advanced and metastatic breast cancer. Offered in Polymorphic Form A with purity greater than 98%, produced in OEB 4 GMP-compliant facilities with full DMF and CTD regulatory documentation.
  • Suanfarma CDMO Services Contract Development and Manufacturing Organization services offering integrated end-to-end solutions for API development and manufacturing, combining fermentation and chemical synthesis capabilities. Spans process development, technology transfer, scale-up, and commercial GMP manufacturing for pharmaceutical and biotech partners.
  • Fermentation Services Industrial-scale bioconversion through fermentation processes that produce complex molecular intermediates from renewable raw materials using bacteria, yeast, or fungi. Includes lab-to-industrial-scale production of APIs and intermediates among the largest fully GMP-compliant fermentation operations in Europe.
  • Chemical Synthesis Services Precision chemical synthesis capabilities for API production, including complex reactions, hydrogenations, distillations, crystallizations, and drying processes, integrated with fermentation in modular hybrid production lines for efficient campaign transitions.
  • Regulatory and Technical Support Services Comprehensive technical and regulatory package including DMF and CTD documentation, polymorphic form confirmation, impurity characterization, CEP support, and compliance assistance for global market registration across 70+ regulatory markets.
  • Co-Development Services Collaborative product development, regulatory strategy, and dossier preparation services for pharmaceutical and biotech partners, leveraging Suanfarma's fermentation and chemical synthesis platform and global regulatory expertise.

Quantifiable outcome

  • 20-30% reduction in technology transfer timelines through Digital Twin technology
  • +2 more outcomes

Companies that use Suanfarma Biotech

Customer profile

Segments3 records

Ideal customer profiles2 records

Suanfarma Biotech technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Suanfarma Biotech partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Fundación Lucha contra las InfeccionescoreStrategic or Co-development Partner · 27 November 2025Strategic collaboration between Suanfarma and the Fight Infections Foundation (Fundación Lucha contra las Infecciones), a non-profit entity with over 30 years of scientific leadership in infectious disease research, prevention, and treatment. The partnership supports advanced research in critical areas for global health including HIV, COVID-19, and neglected diseases, aligning with Suanfarma's API development and supply activities.
  • la Caixa FoundationminorStrategic or Co-development Partner · 8 November 2023Suanfarma joined the Child Vaccination Alliance, an initiative established by la Caixa Foundation in collaboration with Gavi, the Vaccine Alliance, and with scientific support from ISGlobal. The alliance provides Spanish companies with an opportunity to contribute to a cooperative project combating child mortality in developing countries. Funds are directed toward vaccine distribution in Mozambique and Ethiopia, targeting pneumonia prevention.
  • Gavi, the Vaccine AllianceminorStrategic or Co-development Partner · 8 November 2023Suanfarma participates in the Child Vaccination Alliance alongside Gavi, contributing to vaccination programs for children under 5 in 73 of the world's poorest countries. la Caixa Foundation and the Bill and Melinda Gates Foundation match donations up to 2 million euros.
  • Fundación ArraigominorOthersSuanfarma founded and serves as patron of Fundación Arraigo, established to help migrants in Spain by providing basic education and resources to facilitate labor integration. The foundation has supported 1,950 people, 560 families, and delivered 750 diplomas across multiple training and employment projects.
  • UQUIFAcoreChannel Partner/ Reseller/ DistributorSuanfarma distributes Albendazole manufactured by UQUIFA at its plant in Mexico. This partnership enables Suanfarma to offer antiparasitic APIs under high quality and accessibility standards, combining UQUIFA's manufacturing capabilities with Suanfarma's global distribution network.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Suanfarma Biotech competitors and assessment

Company assessment

Broad incumbents

  • Fareva: French privately-held pharmaceutical manufacturer covering APIs, finished dosage forms and cosmetics/industrial manufacturing across Europe. Broad European incumbent with overlapping CDMO/API capabilities.
  • Cambrex: US-headquartered CDMO owned by Permira, focused on small-molecule API development and manufacturing. Established global CDMO incumbent overlapping with Suanfarma's small-molecule API offerings.
  • Recipharm: Large Swedish CDMO (PE-owned by EQT) covering APIs, finished dosage forms and biologics across many sites. Broader CDMO incumbent that competes with Suanfarma for complex API outsourcing contracts.
  • WuXi STA (WuXi AppTec): Chinese CDMO covering small-molecule API and integrated CMC services globally. Representative of the Asian low-cost CDMO competitors against which Suanfarma's European dual-sourcing positioning is increasingly sold.

Direct peers

  • Siegfried Holding: Swiss-listed CDMO offering integrated API manufacturing including controlled substances and fermentation-derived molecules, with dual-site European production. Closely comparable in scope, regulatory depth and CDMO platform strategy.
  • Carbogen Amcis: Swiss-headquartered CDMO specializing in API development, including fermentation-derived and highly potent compounds, with Indian manufacturing via the Dishman site. Comparable in fermentation + high-potency API niche.
  • AGC Pharma Chemicals: CDMO arm of AGC offering small-molecule API development and manufacturing including fermentation and chemical synthesis capabilities. Competes directly with Suanfarma CDMO for similar innovator and generic API projects.
  • EuroAPI: European API manufacturer spun out of Sanofi in 2022, focused on small-molecule APIs across multiple therapeutic areas with global customer reach. Directly comparable in product portfolio and European industrial API footprint.
  • Hovione: Portugal-headquartered CDMO combining chemistry, fermentation and particle engineering for small-molecule APIs. Closest geographic and capability analogue to Suanfarma's Cipan/Portuguese footprint and dual fermentation-chemical synthesis model.
  • Olon Group: Italian CDMO and one of the largest global manufacturers of generic APIs with fermentation and chemical synthesis capabilities across multiple sites. Direct European-headquartered peer with overlapping capabilities to Cipan and Rovereto.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

Suanfarma Biotech social profiles

Digital presence

Suanfarma Biotech compliance and trust

Trust signal

Compliance3 records

Suanfarma Biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Suanfarma Biotech leadership team

Management profile

Number of profiles

Profiles7 records

Suanfarma Biotech subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Suanfarma Biotech funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Suanfarma Biotech M&A and investment

M&A and investment

M&A1 record

Investments4 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Suanfarma Biotech

What does Suanfarma Biotech do?

Suanfarma Biotech develops, manufactures, and globally distributes Active Pharmaceutical Ingredients (human APIs, veterinary APIs, and intermediate products) and provides integrated Contract Development and Manufacturing Organization (CDMO) services combining fermentation and chemical synthesis. Manufacturing is performed at two European GMP-compliant facilities (Cipan in Portugal, Rovereto in Italy) and supplied to pharmaceutical and biotech customers in 75+ countries via direct enterprise sales backed by 10 commercial offices.

Is Suanfarma Biotech a public or private company?

Suanfarma Biotech is a private company. It is classified as private equity controlled and is currently operating.

When was Suanfarma Biotech founded?

Suanfarma Biotech was founded in 2019. It employs 101 to 250 people.

Where is Suanfarma Biotech based?

Suanfarma Biotech is headquartered in Madrid, Spain, in the Europe region.

How does Suanfarma Biotech make money?

Three revenue lines are on record. Active Pharmaceutical Ingredients (API) Sales are the primary driver. The others are CDMO (Contract Development and Manufacturing Organization) Services and co-Development and Regulatory Consulting.

Who are Suanfarma Biotech's main competitors?

Broad incumbents on record are Fareva, Cambrex, Recipharm and WuXi STA (WuXi AppTec). Direct peers are Siegfried Holding, Carbogen Amcis, AGC Pharma Chemicals, EuroAPI, Hovione and Olon Group.

Does Suanfarma Biotech have an API?

No public API is recorded for Suanfarma Biotech.

What industry is Suanfarma Biotech in?

Suanfarma Biotech's product category is Active Pharmaceutical Ingredient (API) Manufacturing and CDMO Services. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAIABAI, Contract Development & Manufacturing for Generics (CDMO/CMO). Its NAICS code is 325411 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Startup BusinessEfficienza energetica con l’Ia, Alperia porta a ‘Cphi Milan’ la decarbonizzazione che entra in fabbricaAlperia presented its energy efficiency and decarbonization solutions at Cphi Milan 2026, focusing on pharmaceutical industry applications. Its Sybil AI platform has delivered over 30% energy savings at Venice Airport and 40% at 24 Ore, and a case study at Suanfarma demonstrated reduced consumption and process stability.TalkMarketsVeterinary API Market Size, Trends, and Growth Outlook 2026-2033The global veterinary API market is projected to grow from USD 9.97 billion in 2026 to USD 16.43 billion by 2033, driven by rising animal healthcare spending and demand for companion animal products. Key players such as Zoetis Inc and SUANFARMA S.A are implementing strategic investments and partnerships to enhance supply chain resilience amid geopolitical disruptions and regulatory changes. Innovations in synthesis technologies and diversification of raw material sourcing are central to the industry's growth strategy.Polaris Market ResearchU.S. Veterinary Active Pharmaceutical Ingredients Manufacturing Market 2034A market research report forecasts the U.S. veterinary active pharmaceutical ingredients manufacturing market to grow from USD 2.98 billion in 2024 to USD 4.97 billion by 2034, driven by rising pet ownership and animal health expenditure. The industry landscape is characterized by a competition between integrated giants like Zoetis and Merck Animal Health, which prioritize in-house production, and specialized contract manufacturers such as Huateng Pharma and SUANFARMA. Key growth segments include antiparasitics for livestock and advanced therapies for companion animals, with AI increasingly utilized to optimize drug discovery and manufacturing efficiency.openPR.comVeterinary API Market Report - Vaccines, Anti-Infectives & Biological APIs Analysis | Top Companies SUANFARMA, Alivira Animal Health Limited & Zoetis.The global veterinary API market was valued at US$6.84 billion in 2023 and is projected to reach US$12.29 billion by 2031, a CAGR of 7.6%. Vaccines held a 56.5% market share in 2024, with North America leading and Asia-Pacific growing fastest. Recent developments include EUROAPI's €130-150 million contract and Indian Immunologicals' Rs.700 crore vaccine facility.SuanfarmaInnovative Strategies for a More Sustainable IndustrySuanfarma is implementing a comprehensive sustainability strategy for pharmaceutical manufacturing, focusing on green chemistry, renewable energy adoption, and advanced water conservation technologies. The company aligns its Environmental, Social, and Governance (ESG) efforts with the Corporate Sustainability Reporting Directive (CSRD) to enhance transparency and operational efficiency. These initiatives aim to reduce carbon footprints and hazardous waste while ensuring regulatory compliance in global markets.PR NewswireWILLOW BIOSCIENCES REPORTS FOURTH QUARTER AND FISCAL YEAR 2023 FINANCIALS AND OPERATIONS AND FILING OF ITS 2023 AIFWillow Biosciences Inc. reported fiscal year 2023 results with record revenue of $1.2 million, representing 43% growth over 2022, while continuing to expand its partnership portfolio with four new collaborations including agreements with Suanfarma and Kalsec. The company completed a restructuring moving all operations to Sunnyvale, California and closed an $800,000 financing, though it reported a net loss of $13.0 million with cash declining to $3.1 million. For 2024, Willow expects significant revenue growth exceeding 100% year-over-year and anticipates executing commercial agreements on its corticosteroid programs.PR NewswireSUANFARMA annonce une collaboration avec Reyoung Pharmaceutical afin d'élargir le portefeuille existant de produits anti-infectieux et antibactériensSUANFARMA, a Spanish pharmaceutical company specializing in active pharmaceutical and nutritional substances, has entered into a strategic collaboration agreement with Reyoung Pharmaceutical, a Chinese manufacturer established in 1966, to expand their joint portfolio of anti-infectious and antibacterial active pharmaceutical ingredients. The partnership combines SUANFARMA's proprietary flow chemistry technology—which improves reaction yields, selectivity, and environmental safety—with Reyoung's established manufacturing capabilities to address ongoing supply chain shortages and uncertainty in the global pharmaceutical industry. Both companies have indicated this agreement marks the beginning of a broader partnership they expect to be highly promising for patients.PR NewswireSUANFARMA anuncia una colaboración con Reyoung Pharmaceutical para ampliar la cartera existente de productos antiinfecciosos y antibacterianos.SUANFARMA announced a strategic collaboration with Reyoung Pharmaceutical to expand its portfolio of anti-infective and antibacterial active pharmaceutical ingredients. The agreement combines SUANFARMA's internally developed flow chemistry technology with Reyoung's manufacturing capabilities, established since 1966, to ensure supply of essential medications amid global pharmaceutical supply chain uncertainties. Both companies expect this bilateral cooperation to yield promising results for patients in the human and animal health sectors.PR NewswireWillow y Suanfarma anuncian una colaboración para el desarrollo de API antiinfectivo de gran volumenWillow Biosciences Inc. and SUANFARMA have announced a collaboration agreement to develop a high-volume anti-infective active pharmaceutical ingredient (API) through precision fermentation, with SUANFARMA gaining access to Willow's patented strain optimization technologies. The partnership aims to enable more cost-effective commercial production at SUANFARMA's manufacturing facility. This announcement marks further expansion of a relationship that began in March 2023, when the two companies first announced an alliance to work on pharmaceutical and biotech capabilities for synthetic molecules.PR NewswireWILLOW ET SUANFARMA ANNONCENT LEUR COLLABORATION POUR LE DÉVELOPPEMENT D'UN GRAND VOLUME D'API ANTI-INFECTIEUX PAR LE BIAIS DE LA FERMENTATION DE PRÉCISIONWillow Biosciences and SUANFARMA announced the signing of a collaboration agreement for a cell line productivity optimization program to manufacture high-volume anti-infectious active pharmaceutical ingredients (APIs) through precision fermentation. Under the agreement, SUANFARMA gains access to Willow's exclusive strain optimization technologies to develop a more cost-effective commercial production process at its manufacturing site in Europe. The announcement marks a further expansion of the relationship established in March 2023, when the two companies first entered an alliance to work on pharmaceutical and biotechnological capabilities including anti-infectious APIs.